Harvey-ras gene expression and epidermal cell proliferation in dibenzo[a,I]pyrene-treated early preneoplastic SENCAR mouse skin

Journal of Investigative Dermatology

Volumn 125, Issue 3, 2005, Pages 567-574

  Khan, Gausal A ^a   Bhattacharya, Gautam ^b   Mailander, Paula C ^a   Meza, Jane L ^a   Hansen, Laura A ^c   Chakravarti, Dhrubajyoti ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dibenzo a,i pyrene; H ras; Initiated cell; Mouse skin; Proliferation

Indexed keywords

BENZO[A]PYRENE DERIVATIVE; BENZO[RST]PENTAPHENE; CARCINOGEN; CYCLIN D1; CYCLIN D2; CYCLIN E; DIMETHYLBENZ[A]ANTHRACENE; DNA; GUANOSINE TRIPHOSPHATE; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG; CYCLIN G; CYCLINE; DIBENZO(A,L)PYRENE; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS CELL; FEMALE; GENE EXPRESSION; GENE MUTATION; KERATINOCYTE; KINETICS; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; SKIN CANCER; SKIN CARCINOGENESIS; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EPIDERMIS; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; PRECANCER; SENSITIVE TO CARCINOGENESIS MOUSE; SKIN TUMOR;

ANIMALS; BENZOPYRENES; CELL PROLIFERATION; CYCLINS; EPIDERMIS; FEMALE; GENE EXPRESSION; GENES, RAS; MICE; MICE, INBRED SENCAR; MUTATION; PRECANCEROUS CONDITIONS; RAS PROTEINS; SKIN NEOPLASMS;

EID: 27144546804     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2005.23845.x     Document Type: Article

References (53)

1. Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z, Wittinghofer A, Scheffzek K: Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci USA 96:7065-7070, 1999
2. Andreasen E: Cyclic changes in the skin of the mouse. Acta Pathol Scand 32:157-164, 1953
3. Barbacid M: Ras oncogenes: Their role in neoplasia. Eur J Clin Invest 20:225-235, 1990
4. Bianchi AB, Fischer SM, Robles AI, Rinchik EM, Conti CJ: Overexpression of cyclin D1 in mouse skin carcinogenesis. Oncogene 8:1127-1133, 1993
5. Bickenbach JR, McCutecheon J, Mackenzie IC: Rate of loss of tritiated thymidine label in basal cells in mouse epithelial tissues. Cell Tissue Kinet 19:325-333, 1986
6. Bos JL: Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
7. Casale GP, Cheng Z, Liu J, Cavalieri EL, Singhal M: Profiles of cytokine mRNAs in the skin and lymph nodes of SENCAR mice treated epicutaneously with dibenzo[a,I]pyrene or dimethylbenz[a]anthracene reveal a direct correlation between carcinogen-induced contact hypersensitivity and epidermal hyperplasia. Mol Carcinogen 27:125-140, 2000
8. Casale GP, Higginbotham S, Johansson SL, Rogan EG, Cavalieri EL: Inflammatory response of mouse skin exposed to the very potent carcinogen dibenzo[a,I]pyrene: A model for tumor promotion. Fundam Appl Toxicol 36:71-78, 1997
9. Chakravarti D, Bhattacharya G, Mailander PC: Repression of replication and induction of base excision repair in dibenzo[a,I]pyrene-treated SENCAR mouse skin. Proc Am Assoc Cancer Res 45:1560, 2004
10. Chakravarti D, Mailander P, Cavalieri EL, Rogan EG: Evidence that error-prone DNA repair converts dibenzo[a,I]pyrene-induced depurinating lesions into mutations: Formation, clonal proliferation and regression of initiated cells carrying H-ras oncogene mutations in early preneoplasia. Mutation Res 456:17-32, 2000
11. Chakravarti D, Mailander P, Franzen J, Higginbotham S, Cavalieri EL, Rogan EG: Detection of dibenzo[a,I]pyrene-induced H-ras codon 61 mutant genes in preneoplastic SENCAR mouse skin using a new PCR-RFLP method. Oncogene 16:3203-3210, 1998
12. Chakravarti D, Pelling JC, Cavalieri EL, Rogan EG: Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: The role of apurinic sites. Proc Natl Acad Sci USA 92:10422-10426, 1995
13. Crespo P, Leon J: Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 57:1613-1636, 2000
14. Dover R: Cell kinetics of keratinocytes. In: Leigh IMLEB, Watt FM (eds). The Keratinocyte Handbook. Cambridge: Cambridge University Press, 1994; p 203-234
15. Engvall E, Perlmann P: Enzyme-linked immunosorbent assay (ELISA): Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes. J Immunol 109:129-135, 1972
16. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE: Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxford) 50:529-535, 1999
17. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr: Oncogenic Ha-ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272:24113-24116, 1997
18. Geisen C, Moroy T: The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J Biol Chem 277:39909-39918, 2002
19. Grendys EC Jr, Barnes WA, Weitzel J, Sparkowski J, Schlegel R: Identification of H, K, and N-ras point mutations in stage IB cervical carcinoma. Gynecol Oncol 65:343-347, 1997
20. Gyongyi Z, Grama L, Nadasi E, et al: Flow cytometric analysis of DMBA-induced early in vivo ras expression. In Vivo 16:323-326, 2002
21. Johnson R, Spiegelman B, Hanahan D, Wisdom R: Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16:4504-4511, 1996
22. Kemp CJ, Burns PA, Brown K, Nagase H, Balmain A: Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. In: Cold Spring Harbor Symposia on Quantitative Biology. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1994; p 427-434
23. Krengel U, Schlichting L, Scherer A, et al: Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell 62:539-548, 1990
24. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
25. Langer SJ, Bortner DM, Roussel MF, Sherr CJ, Ostrowski MC: Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol Cell Biol 12:5355-5362, 1992
26. Li D, Firozi PF, Zhang W, et al: DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res 513:37-48, 2002
27. Ludde T, Kubicka S, Plumpe J, Liedtke C, Manns MP, Trautwein C: Ras adeno-viruses modulate cyclin E protein expression and DNA synthesis after partial hepatectomy. Oncogene 20:5264-5278, 2001
28. McCullagh P, Neider JA: Generalized Linear Models. London: Chapman & Hall, 1989
29. Malumbres M, Barbacid M: Ras oncogenes: The first 30 years. Nat Rev Cancer 3:459-465, 2003
30. Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML: Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23:1863-1873, 2004
31. Morris RJ: Keratinocyte stem cells: Targets for cutaneous carcinogens. J Clin Invest 106:3-8, 2000
32. Morris RJ, Coulter K, Tryson K, Steinberg SR: Evidence that cutaneous carcinogen-initiated epithelial cells from mice are quiescent rather than actively cycling. Cancer Res 57:3436-3443, 1997
33. Morris RJ, Fischer SM: A defined culture system for epidermal keratinocytes from adult mice. In: IM Leigh, Lane EB, Watt FM (eds). The Keratinocyte Handbook. Cambridge: Cambridge University Press, 1994; p 53-69
34. Morris RJ, Fischer SM, Slaga TJ: Evidence that a slowly cycling subpopulation of adult murine epidermal cells retains carcinogen. Cancer Res 46:3061-3066, 1986
35. Morris RJ, Potten CS: Slowly cycling (label-retaining) epidermal cells behave like clonogenic stem cells in vitro. Cell Prolif 27:279-289, 1994
36. Morris RJ, Tryson KA, Wu KQ: Evidence that the epidermal targets of carcinogen action are found in the interfollicular epidermis of infundibulum as well as in the hair follicles. Cancer Res 60:226-229, 2000
37. Nagase H, Mao JH, Balmain A: Allele-specific H-ras mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. Cancer Res 63:4849-4853, 2003
38. Osaka M, Matsuo S, Koh T, Sugiyama T: Specific N-ras mutation in bone marrow within 48 h of 7, 12-dimethylbenz[a]anthracene treatment in Huggins-Sugiyama rat leukemogenesis. Mol Carcinogen 16:126-131, 1996
39. Robles AI, Conti CJ: Early overexpression of cyclin D1 protein in mouse skin carcinogenesis. Carcinogenesis 16:781-786, 1995
40. Robles AI, Rodriguez-Puebla ML, Glick AB, et al: Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12:2469-2474, 1998
41. Rodriguez-Puebla ML, LaCava MM, Bolontrade F, Russell J, Conti CJ: Increased expression of mutated Ha-ras during premalignant progression in SEN-CAR mouse skin. Mol Carcinogen 26:150-156, 1999a
42. Rodriguez-Puebla ML, LaCava M, Gimenez-Conti IB, Johnson DG, Conti CJ: Deregulated expression of cell cycle proteins during premalignant progression in SENCAR mouse skin. Oncogene 17:2251-2258, 1998
43. Rodriguez-Puebla ML, Robles AI, Conti CJ: Ras activity and cyclin D1 expression: An essential mechanism of mouse skin tumor development. Mol Carcinogen 24:1-6, 1999b
44. Roop DR, Lowy DR, Tambourin PE, et al: An activated Harvey-ras oncogene produces benign tumours on mouse epidermal tissue. Nature 323:822-824, 1986
45. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A: The Ras-RasGAP complex: Structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277:333-338, 1997
46. Semczuk A, Schneider-Stock R, Berbec H, Marzec B, Jakowicki JA, Roessner A: K-ras exon 2 point mutations in human endometrial cancer. Cancer Lett 164:207-212, 2001
47. Shiraishi T, Muneyuki T, Fukutome K, Ito H, Kotake T, Watanabe M, Yatani R: Mutations of ras genes are relatively frequent in Japanese prostate cancers: Pointing to genetic differences between populations. Anticancer Res 18:2789-2792, 1998
48. Sklar MD, Thompson E, Welsh MJ, et al: Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol Cell Biol 11:3699-3710, 1991
49. Starkel P, Lambotte L, Sempoux C, De Saeger C, Saliez A, Maiter D, Horsmans Y: After portal branch ligation in the rat, cellular proliferation is associated with selective induction of c-Ha-ras, p53, cyclin E, and Cdk2. Gut 49: 119-130, 2001
50. Telford WG, King LE, Fraker PJ: Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif 24:447-459, 1991
51. Vahakangas KH, Bennett WP, Castren K, et al: p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 61:4350-4356, 2001
52. van der Schroeff JG, Evers LM, Boot AJ, Bos JL: Ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol 94:423-425, 1990
53. Zhu S, Yoon K, Sterneck E, Johnson PF, Smart RC: CCAAT/enhancer binding protein-beta is a mediator of keratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. Proc Natl Acad Sci USA 99:207-212, 2002